Teva Pharmaceutical Is Getting a Beating Between Analysts and Credit Rating Agencies Who See Valuation Heading Down the Drain

Teva Pharmaceutical (NYSE:TEVA) investors have seen a once strong Israeli pharma giant stumble 71% from its former valuation glory, and some on the Street fear another 50% fall from grace is still coming investors’ way. HSBC  analyst Steve McGarry and Wells Fargo analyst Davis Maris prepare for the worst.

Story Continues

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts